Novartis
NEWS
The legal ruling, subject to appeal, protects the Swiss pharma giant’s revenue stream from the blockbuster drug Gilenya for a little bit longer.
Novartis plans to make the drugs available to government, non-governmental organizations (NGOs) and other institutional customers in up to 79 countries at no profit.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.
Novartis is the first company to the finish line with an approved treatment for Adult-Onset Still’s Disease (AOSD), a rare autoinflammatory disease of unknown origin.
On Tuesday, the FDA extended its review of the Supplemental Biologics License Application for Arzerra in this indication by three months.
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 11, 2020.
Dyno says that with its research-and-development and collaboration deals with biopharma companies, it is potentially eligible for more than $2 billion in upfront payments, research support, and various milestones and option fees.
JOBS
IN THE PRESS